Navco Pharmaceuticals Inc.
NAV.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -96.76% | -98.40% | -97.53% | -82.82% | -77.13% |
| Depreciation & Amortization | -- | -97.50% | -93.83% | -93.90% | 222.78% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -97.48% | -98.34% | -97.37% | -82.98% | -71.21% |
| Operating Income | 97.48% | 98.34% | 97.37% | 82.98% | 71.21% |
| Income Before Tax | 93.75% | 95.72% | 96.25% | -164.56% | 94.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.75% | 95.72% | 96.25% | -164.56% | 94.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.75% | 95.72% | 96.25% | -164.56% | 94.79% |
| EBIT | 97.48% | 98.34% | 97.37% | 82.98% | 71.21% |
| EBITDA | 109.26% | 102.24% | 103.23% | 84.74% | 77.12% |
| EPS Basic | 95.65% | 96.36% | 98.00% | -145.75% | 96.27% |
| Normalized Basic EPS | 93.33% | 97.06% | 96.77% | 87.78% | 76.92% |
| EPS Diluted | 95.65% | 96.36% | 98.00% | -145.75% | 96.27% |
| Normalized Diluted EPS | 93.33% | 97.06% | 96.77% | 87.78% | 76.92% |
| Average Basic Shares Outstanding | 2.98% | 6.22% | 41.43% | 41.53% | 37.34% |
| Average Diluted Shares Outstanding | 2.98% | 6.22% | 41.43% | 41.53% | 37.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |